MedTrace Logo

Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer

NCT00658580 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 361

Last updated 2015-02-12

No results posted yet for this study

Summary

The purpose of this study is to determine if a cisplatin-etoposide regimen improves survival in comparison to a regimen containing etoposide and without platinum derivative.

Conditions

  • Small Cell Lung Carcinoma, Extensive Disease

Interventions

DRUG

Cisplatin + etoposide

Cisplatin 90 mg/m² day 1, every 3 weeks Etoposide 100 mg/m² days 1-3, every 3 weeks

DRUG

Epirubicin + ifosfamide + etoposide

Epirubicin 60 mg/m² day 1, every 3 weeks Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks Etoposide 100 mg/m² days 1-3, every 3 weeks

Sponsors & Collaborators

  • European Lung Cancer Working Party

    lead OTHER

Principal Investigators

  • Jean-Paul Sculier, MD, PhD · European Lung Cancer Working Party

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-04-30
Primary Completion
2013-12-31
Completion
2015-02-28

Countries

  • Belgium
  • France
  • Greece
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00658580 on ClinicalTrials.gov